- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01635907
Dovitinib in Neuroendocrine Tumors
April 9, 2020 updated by: Abramson Cancer Center of the University of Pennsylvania
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma
This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors.
This study will also further evaluate the safety of this drug.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This investigator-initiated study is being conducted to evaluate whether the investigational drug, Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors (advanced malignant pheochromocytoma or paraganglioma).
The primary endpoint will be response rate (Complete + Partial Response) determined by RECIST v 1.1.
25 subjects will be enrolled on this study at the University of Pennsylvania.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Abramson Cancer Center of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with advanced, metastatic, recurrent or unresectable paraganglioma or pheochromocytoma. Pathology report or pathology slides (H&E) confirming histological diagnosis must be available at the time of enrollment.
- Must have measurable disease by RECIST v1.1.
- ECOG performance status 0, 1, 2
- Age greater or equal to 18 years old
- Adequate laboratory results; negative pregnancy test (females of childbearing potential)
- Patients who give a written informed consent obtained according to institutional guidelines
Exclusion Criteria:
- Patients with known untreated brain metastases are excluded. Patients having a history of brain metastasis that have been previously irradiated or resected greater than 3 months prior to enrollment and are clinically and radiographically stable will be considered for enrollment.
- Patients with another primary malignancy within 3 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, or skin cancer (such as basal cell carcinoma, squamous cell carcinoma, or non-melanomatous skin cancer)
- Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosurea, mitomycin-C, targeted therapy and radiation) less than or equal to 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
- Patients who have received the last administration of nitrosurea or mitomycin-C less than or equal to 6 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
- Patients who have received bevacizumab, sunitinib, sorafenib, or pazopanib less than or equal to 2 weeks prior to starting study drug, or who have not recovered (grade 1) from the side effects of these therapies.
- Patients who have had radiotherapy less than or equal to 4 weeks prior to starting study drug, or less than or equal to 2 weeks prior to starting study drug in the case of localized radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture), or who have not recovered from radiotherapy toxicities
- Patients who have had therapeutic radiolabeled MIBG or other systemic radiolabeled therapy less than or equal to 4 weeks prior to starting study drug,
- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury less than or equal to 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
- Patients with any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study (i.e. impaired cardiac function or clinically significant cardiac diseases, etc).
- Pregnant or breastfeeding women or any subjects who refuse to use protocol required contraception
- Patients unwilling or unable to comply with the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dovitinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to determine the objective response rate of dovitinib in subjects with advanced malignant pheochromocytoma or paraganglioma
Time Frame: 2 years
|
using RECIST criteria
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (ACTUAL)
March 1, 2016
Study Completion (ACTUAL)
April 11, 2016
Study Registration Dates
First Submitted
July 5, 2012
First Submitted That Met QC Criteria
July 9, 2012
First Posted (ESTIMATE)
July 10, 2012
Study Record Updates
Last Update Posted (ACTUAL)
April 14, 2020
Last Update Submitted That Met QC Criteria
April 9, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 23811
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Paraganglioma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland PheochromocytomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Adrenal Gland Pheochromocytoma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Advanced Adrenal Gland Pheochromocytoma | Advanced Paraganglioma | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | Stage...United States
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
National Cancer Institute (NCI)TerminatedParaganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal ParagangliomaUnited States, Singapore, Hong Kong
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMetastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditionsUnited States
-
Pamukkale UniversityCompletedHead and Neck ParagangliomaTurkey
-
Assistance Publique - Hôpitaux de ParisSociety for EndocrinologyRecruitingParaganglioma of Head and NeckFrance
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingAdvanced or Metastatic Paraganglioma/ PheochromocytomaChina
-
Seoul National University HospitalCompletedPheochromocytoma | Extra-adrenal Paraganglioma | Non-functioning CarcinoidKorea, Republic of
-
Gustave Roussy, Cancer Campus, Grand ParisNational Cancer Institute, France; European Network for the Study of Adrenal...CompletedMalignant Progressive Pheochromocytoma and Paraganglioma (PPGL)Italy, France, Germany, Netherlands
Clinical Trials on Dovitinib
-
Novartis PharmaceuticalsCompletedNeoplasms | Cancer | TumorsUnited States
-
Yonsei UniversityCompletedThyroid CancerKorea, Republic of
-
Samsung Medical CenterUnknownSquamous NSCLCKorea, Republic of
-
Korean Cancer Study GroupCompletedHormone Refractory Prostate CancerKorea, Republic of
-
Novartis PharmaceuticalsCompletedTumor Pathway Activations Inhibited by DovitinibUnited States
-
Novartis PharmaceuticalsCompletedEndometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line TreatmentItaly, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandUnknownClear Cell Renal Cell CarcinomaNew Zealand
-
Novartis PharmaceuticalsCompletedMetastatic Breast CancerUnited States, Canada, Finland, France, Italy, Spain, Taiwan, United Kingdom
-
M.D. Anderson Cancer CenterNovartisTerminated
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors | Excluding Breast CancerUnited States